EntryPoint Capital LLC Has $226,000 Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

EntryPoint Capital LLC trimmed its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 39.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,586 shares of the biotechnology company’s stock after selling 1,701 shares during the period. EntryPoint Capital LLC’s holdings in Blueprint Medicines were worth $226,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BPMC. Wellington Management Group LLP increased its position in shares of Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after buying an additional 729,055 shares during the period. State Street Corp grew its holdings in Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after acquiring an additional 385,818 shares during the period. Jennison Associates LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth about $31,417,000. Jacobs Levy Equity Management Inc. raised its position in shares of Blueprint Medicines by 161.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock worth $45,888,000 after acquiring an additional 306,079 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in Blueprint Medicines by 16.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock worth $169,616,000 after acquiring an additional 269,896 shares in the last quarter.

Insider Activity

In other news, insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at approximately $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,608 shares of company stock valued at $3,319,587 over the last quarter. Company insiders own 4.21% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Stephens reaffirmed an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a research report on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. StockNews.com lowered Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Finally, Jefferies Financial Group began coverage on Blueprint Medicines in a report on Monday, March 17th. They set a “buy” rating and a $135.00 price target for the company. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $88.72 on Friday. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock’s fifty day moving average price is $98.13 and its two-hundred day moving average price is $93.99. The firm has a market cap of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.